Overexpression of <i>corp</i><sup><i>+</i></sup> suppresses the BARTL phenotype.

<p>(A) The range of eye phenotypes observed in the assay. The <i>B</i><sup><i>S</i></sup> phenotype of <i>H1</i> control males is shown at the left. When FLP is expressed (<i>ey>FLP</i>), the phenotypes can range from headless pharates (category 1) to adults with a fully developed wildtype eye (category 5). The distribution produced (B) in control males; (C) in males carrying <i>P{EPgy2}EY03495</i>, referred to as <i>EP-corp</i><sup><i>+</i></sup>; (D) by inclusion of a <i>UAS-corp</i><sup><i>+</i></sup> transgene; (E) with RNAi-mediated knockdown of <i>corp</i>; (F) in <i>corp</i><sup><i>95B</i></sup> mutants; (G) with rescue of the <i>corp</i><sup><i>95B</i></sup> phenotype by expression from the <i>UAS-corp</i><sup><i>+</i></sup> transgene; and, (H) with RNAi-mediated knockdown of <i>CG1632</i>. N represents number of eyes scored for each genotype. Each <i>P</i> value represents comparison with the wildtype control, shown in B. Genotypes were: (B) <i>y w/H1; eyGal4 UAS-FLP/+</i>; (C) <i>y w EP-corp</i><sup><i>+</i></sup><i>/H1; eyGal4 UAS-FLP/+</i>; (D) <i>y w/H1; eyGal4 UAS-FLP/+; UAS-corp</i><sup><i>+</i></sup><i>/+</i>; (E) <i>y w/H1; eyGal4 UAS-FLP/RNAi-corp</i>; (F) <i>y w corp</i><sup><i>95B</i></sup><i>/H1; eyGal4 UAS-FLP/+</i>; (G) <i>y w corp</i><sup><i>95B</i></sup><i>/H1; eyGal4 UAS-FLP/+; UAS-corp</i><sup><i>+</i></sup><i>/+</i>; (H) <i>y w/H1; eyGal4 UAS-FLP/RNAi-CG1632</i>.</p>